# Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

> **NCT05867615** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 83 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** [177Lu]Lu-PSMA I&T

## Key facts

- **NCT ID:** NCT05867615
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-25
- **Primary completion:** 2026-08
- **Final completion:** 2028-12
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867615, "Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05867615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*